Meng M, Zhang WW, Chen SF, Wang DR, Zhou CH. Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects. World J Stem Cells 2024; 16(2): 70-88 [PMID: 38455096 DOI: 10.4252/wjsc.v16.i2.70]
Corresponding Author of This Article
Chang-Hui Zhou, MD, Doctor, Department of Central Laboratory, Liaocheng People’s Hospital, No. 67 Dongchang West Road, Liaocheng 252000, Shandong Province, China. zhouchanghui008@163.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Feb 26, 2024; 16(2): 70-88 Published online Feb 26, 2024. doi: 10.4252/wjsc.v16.i2.70
Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects
Min Meng, Wei-Wei Zhang, Shuang-Feng Chen, Da-Rui Wang, Chang-Hui Zhou
Min Meng, Wei-Wei Zhang, Shuang-Feng Chen, Chang-Hui Zhou, Department of Central Laboratory, Liaocheng People’s Hospital, Liaocheng 252000, Shandong Province, China
Da-Rui Wang, Department of Clinical Laboratory, Liaocheng People’s Hospital, Liaocheng 252000, Shandong Province, China
Co-first authors: Min Meng and Wei-Wei Zhang.
Co-corresponding authors: Chang-Hui Zhou and Da-Rui Wang.
Author contributions: Meng M and Zhang WW contributed equally to this work. Meng M and Zhang WW collected the references, analyzed clinical trials, and drafted the manuscript; Zhou CH andChen SF contributed to the conception and design of the review; Zhou CH andWang DR critically and systemically revised the manuscript; and all authors read and approved the final manuscript. Zhou CH andWang DR contributed efforts of equal substance in the research process. The choice of these researchers as co-corresponding authors acknowledges and respects this equal contribution. In summary, we believe that designating Zhou CH andWang DR as co-corresponding authors of is fitting for our manuscript as it accurately reflects our team’s equal contributions, collaborative spirit, and diversity.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chang-Hui Zhou, MD, Doctor, Department of Central Laboratory, Liaocheng People’s Hospital, No. 67 Dongchang West Road, Liaocheng 252000, Shandong Province, China. zhouchanghui008@163.com
Received: November 30, 2023 Peer-review started: November 30, 2023 First decision: December 17, 2023 Revised: January 4, 2024 Accepted: January 29, 2024 Article in press: January 29, 2024 Published online: February 26, 2024 Processing time: 87 Days and 19.8 Hours
Abstract
Pulmonary diseases across all ages threaten millions of people and have emerged as one of the major public health issues worldwide. For diverse disease conditions, the currently available approaches are focused on alleviating clinical symptoms and delaying disease progression but have not shown significant therapeutic effects in patients with lung diseases. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) isolated from the human UC have the capacity for self-renewal and multilineage differentiation. Moreover, in recent years, these cells have been demonstrated to have unique advantages in the treatment of lung diseases. We searched the Public Clinical Trial Database and found 55 clinical trials involving UC-MSC therapy for pulmonary diseases, including coronavirus disease 2019, acute respiratory distress syndrome, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, and pulmonary fibrosis. In this review, we summarize the characteristics of these registered clinical trials and relevant published results and explore in depth the challenges and opportunitiesfaced in clinical application. Moreover, the underlying molecular mechanisms involved in UC-MSC-based therapy for pulmonary diseases are also analyzed in depth. In brief, this comprehensive review and detailed analysis of these clinical trials can be expected to provide a scientific reference for future large-scale clinical application.
Core Tip: Pulmonary diseases across all ages threaten millions of people and have emerged as one of the major public health issues worldwide. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are superior for standardization and large-scale production for disease treatment. Herein, we provide a detailed summary of clinical trials and results related to the use of UC-MSCs in the treatment of lung diseases and explore in depth the challenges and opportunities faced in the clinical application of these cells.
